68Ga-DOTATOC and 68Ga-DOTATATE are 2 radiolabeled somatostatin analogs for in vivo
diagnosis of neuroendocrine tumors with PET. The aim of the present work was to measure …

OBJECTIVES: The aim of this pilot study was to explore the impact of peptide mass on
binding of [68Ga]-DOTATOC to neuroendocrine tumour somatostatin receptors in vivo using …

Measured human dosimetry of the 68Ga-labeled synthetic somatostatin analog 68Ga-
DOTATATE has not been reported in the peer-reviewed literature. 68Ga-DOTATATE is an …

Aim: Investigation of the biodistribution and calculation of dosimetry of Ga-68-DOTATOCfor
patients imaged in the routine clinical setting for diagnosis or exclusion of neuroendocrine …

The aim of this study was to evaluate the diagnostic value of a new somatostatin analog,
68Ga-labeled 1, 4, 7, 10-tetraazacyclododecane-N, N′, N ″, N ″′-tetraacetic acid-d …

We hypothesized that 68Ga-DOTATATE uptake of neuroendocrine tumors is sensitive to
therapy with a nonradioactive somatostatin analog. Methods: 68Ga-DOTATATE PET/CT was …

Abstract Purpose PET with 68 Ga-DOTATOC allows for imaging and quantitative
assessment of somatostatin receptor expression in neuroendocrine tumors (NET). The aim …

The aim of this study was to describe the normal physiological distribution of 68 Ga-DOTA-
TATE using the SUV to reflect the density of somatostatin receptors in various organ …

INTRODUCTION: Imaging of somatostatin receptor expressing tumours has been greatly
enhanced by the use of 68Ga-DOTATOC and PET/CT. METHODS: In this work, a purification …

68Ga-labeled 1, 4, 7, 10-tetraazacyclododecane-N, N′, N′′, N′′′-tetraacetic acid-d-
Phe1-Tyr3-octreotide (DOTA-TOC) PET has proven its usefulness in the diagnosis of …